Brief: Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
13/09/2024 12:33
Sept 13 (Reuters) - Immunome Inc IMNM.O :
* IMMUNOME TO PRESENT UPDATED RESULTS FOR RINGSIDE PHASE 2
TRIAL
OF AL102 FOR THE TREATMENT OF DESMOID TUMORS AT THE EUROPEAN
SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS 2024
Source text for Eikon: ID:nBw98gPqpa
Further company coverage: IMNM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immunome
See all newsBrief: Immunome - Enters Amendment No. 4 To License Agreement With Bristol-Myers Squibb Company On Oct 2, 2026
US STOCKS ON THE MOVE-Cardinal Health, nVent, Acuity
U.S. STOCKS ON THE MOVE-Cardinal Health, Fervo Energy, Rocket Lab
U.S. STOCKS ON THE MOVE-Progress Software, Vicor Corp, Accenture
Immunome climbs as Stifel initiates coverage